克罗恩病甲氨蝶呤应答与安全性的遗传生物标志物:西班牙ENEIDA登记数据
该研究基于西班牙ENEIDA登记处,纳入129例仅接受甲氨蝶呤单药治疗的克罗恩病患者,分析ATIC、DHFR、MTHFR、SLC19A1、ABCB1和ABCC3基因多态性与疗效及毒性的关联。结果显示DHFR rs408626和MTHFR rs1801133变异及吸烟与MTX失败风险升高相关,MTHFR rs1801131变异与MTX相关不良反应风险升高相关。
要点
- DHFR rs408626和MTHFR rs1801133变异与克罗恩病患者MTX治疗失败风险升高相关。
- MTHFR rs1801131变异与MTX相关不良反应风险升高相关。
- 吸烟与MTX治疗失败风险升高相关。
核心结论
- MTHFR和DHFR基因变异可能与克罗恩病患者MTX疗效及不良反应相关。
研究设计与样本
- 研究从GETECCU ENEIDA登记处识别仅接受MTX单药治疗且符合入选标准的克罗恩病患者,分析ATIC、DHFR、MTHFR、SLC19A1、ABCB1和ABCC3基因变异与疗效及毒性的关联。
- 共纳入129例患者,MTX中位周剂量为25 mg(四分位距15-25 mg),中位用药时间14个月(四分位距4-52个月)。
主要发现
- 40例(30%)发生MTX相关毒性,导致19%的患者停用MTX。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Methotrexate (MTX) is used to induce and maintain remission in patients with steroid-dependent Crohn's disease (CD). Despite its proven efficacy, its use is limited due to associated adverse events. Polymorphisms involving folate pathway genes might influence MTX efficacy and toxicity. We aimed to assess the impact of certain polymorphisms on the therapeutic outcomes of MTX in CD. METHODS: Patients with CD who exclusively followed MTX monotherapy and fulfilled inclusion criteria were identified from the GETECCU ENEIDA registry. Variants of ATIC, DHFR, MTHFR, SLC19A1, ABCB1 and ABCC3 genes were analysed and their association with efficacy and toxicity was assessed. RESULTS: A total of 129 patients were included in the analysis. MTX was used at a median weekly dose of 25 mg (interquartile range, 15-25 mg) and a median time of 14 months (interquartile range, 4-52 months). Thirty-seven percent of the patients achieved disease remission with MTX monotherapy, while 34% were nonresponders (MTX failure). MTX-related toxicity occurred in 40 patients (30%), leading to MTX discontinuation in 19%. DHFR rs408626 (odds ratio [OR] 3.12, 95% confidence interval [CI] 1.22-7.69; P = .017) and MTHFR rs1801133 (OR 2.86, 95% CI 1.23-6.68; P = .015) variants, and smoking (OR 2.61, 95% CI 1.12-6.05; P = .026) were associated with a higher risk of MTX failure. Additionally, the MTHFR rs1801131 variant was associated with a higher risk of MTX-related adverse effects (OR 2.78, 95% CI 1.26-6.13, P = .011). CONCLUSION: Our study shows that variants of MTHFR and DHFR genes may be associated with MTX efficacy and adverse events in patients with CD.
引用
- Salazar J, Garcia-Planella E, Fernández-Clotet A, et al. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. Br J Clin Pharmacol. 2024. PMID: 38369687. doi:10.1111/bcp.16017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。